Nektar to Webcast Presentation at Jefferies 2017 London Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls more than 3% on weaker global demand outlook and US crude buildup
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Nektar Therapeutics (NKTR) PT Raised to $45 at BTIG Following SITC Meeting
November 13, 2017 8:55 AM ESTBTIG raised its price target on Nektar Therapeutics (NASDAQ: NKTR) to $45.00 (from $35.00) while maintaining a Buy rating. At the Society for Immunotherapy of Cancer meeting (SITC), presentation of oral abstract O20 for NKTR-214, Nektars IL-2-based immune stimulator, was very well received.
NKTR-214 +... More
